慢性阻塞性肺疾病急性加重期患者细菌群谱及药敏分析

doi:10.3969/j.issn.1006-6233.2022.11.033

Abstract
Figure/Table
References
Related Citation (15)

Download: PDF (1178 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective: To analyze of bacterial population spectrum and drug sensitivity in patients with chronic obstructive pulmonary disease (COPD).Methods: The sputum culture data of 212 patients with COPD were retrospectively analyzed between January 2018 and June 2022. The distribution characteristics and drug susceptibility test results of pathogens in sputum culture were analyzed. Results: There were 212 strains of pathogens isolated from sputum culture specimens, including 111 (52.36%) strains of Gram-negative bacteria, 9 (4.24%) strains of Gram-positive bacteria and 92 (43.40%) strains of fungi. In Gram-negative bacteria, proportion of Pseudomonas aeruginosa was the highest (23.11%), followed by Escherichia coli (8.02%). In Gram-positive bacteria, proportion of Streptococcus pneumoniae was the highest (1.89%). In fungi, proportion of Candida albicans was the highest (40.09%). The results of drug sensitivity test showed that Pseudomonas aeruginosa was 100% sensitive to colistin, and the resistance rate to other antibiotics was 6.12% ~ 28.57%; Escherichia coli was 100% sensitive to meropenem and tigecycline, and 94.12% sensitive to imipenem and ertapenem; Klebsiella was 100% sensitive to amikacin, piperacillin tazobactam, cefoperazone sulbactam, imipenem, meropenem, tigecycline and ertapenem, and the resistance rate to other antibiotics was 11.76% ~ 29.41%. Conclusion: The pathogenic bacteria of COPD are mainly Gram-negative bacteria, mainly Pseudomonas aeruginosa and Escherichia coli. It is recommended to refer to the results of drug sensitivity test.

Key words： Chronic obstructive pulmonary disease Airway inflammation Bacterial spectrum Drug sensitivity test

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors

Cite this article:

URL:

http://www.hbyxzzs.cn/EN/10.3969/j.issn.1006-6233.2022.11.033 OR http://www.hbyxzzs.cn/EN/Y2022/V28/I11/1921

[1] Ritchie AI,Wedzicha JA.Definition,causes,pathogenesis,and consequences of chronic obstructive pulmonary disease exacerbations[J].Clin Chest Med,2020,41(3):421-438.
[2] Ditz B,Christenson S,Rossen J,et al.Sputum microbiome profiling in COPD: beyond singular pathogen detection[J].Thorax,2020,75(4):338-344.
[3] 中华医学会呼吸病学分会慢性阻塞性肺疾病学组,中国医师协会呼吸医师分会慢性阻塞性肺疾病工作委员会.慢性阻塞性肺疾病诊治指南(2021年修订版)[J].中华结核和呼吸杂志,2021,44(3):170-205.
[4] Lu Z,Eeckhoutte HP,Liu G,et al.Necroptosis signaling promotes inflammation,airway remodeling,and emphysema in chronic obstructive pulmonary disease[J].Am Respir Crit Care Med,2021,204(6):667-681.
[5] 宋灵洁,李红,程曦.慢性阻塞性肺疾病患者下呼吸道病原菌与死亡影响因素研究[J].成都医学院学报,2021,16(4):477-481.
[6] Flannery DD,Akinboyo IC,Mukhopadhyay S,et al.Antibiotic susceptibility of escherichia coli among infants admitted to neonatal intensive care units across the us from 2009 to 2017[J].JAMA Pediatr,2021,175(2):168-175.
[7] Damiano P,Salema EJ,Silago V.The susceptibility of multidrug resistant and biofilm forming klebsiella pneumoniae and escherichia coli to antiseptic agents used for preoperative skin preparations at zonal referral hospital in Mwanza,Tanzania[J].Malawi Med,2021,33(1): 59-64.
[8] 黄琪,邓俊,王宋平.慢性阻塞性肺疾病对肺部感染病原菌分布与耐药性的影响[J].实用药物与临床,2022,25(6):512-516.
[9] 王姣,郭亚君.慢性阻塞性肺疾病急性加重期合并肺部感染病原学及其预后评估[J].中华医院感染学杂志,2021,31(10):1522-1526.
[10] Wang Y,Oppong TB,Liang X,et al.Methicillin-resistant staphylococcus aureus and vancomycin-resistant enterococci co-colonization in patients: a meta-analysis[J].Am Infect Control,2020,48(8):925-932.
[11] 段友红,张梦兰,夏新红,等.92例COPD急性加重期患者痰液病原菌分布及耐药情况分析[J].实验与检验医学,2020,38(1):123-125.
[12] 习静,脱鸣富,魏育芳,等.不同病程COPD并发下呼吸道感染病原菌分离及耐药情况分析[J].中国抗生素杂志,2020,45(8):798-803.
[13] 何婷媚,吴震,田荣华.慢性阻塞性肺疾病急性加重继发肺真菌感染患者外周血辅助型T细胞17/调节型T细胞及血清细胞因子的变化[J].中国综合临床,2022,38(2):123-128.
[14] 李荷蕊,罗丽娟,曾子航,等.慢性阻塞性肺疾病合并念珠菌病相关危险因素研究进展[J].结核与肺部疾病杂志,2022,3(1):44-49.